Para os poucos pacientes jovens e aptos considerados candidatos ao transplante alogênico de células-tronco (AlloSCT), o objetivo é atingir a remissão completa antes do AlloSCT.
A terapia de indução — com um agente direcionado ou quimioterapia intensiva — é empregada para alcançar a remissão completa antes de prosseguir para o transplante alogênico.
DOI: 10.6004/jnccn.2023.7026
For the few young and fit patients who are considered alloSCT candidates, the aim is to achieve complete remission (CR) prior to alloSCT.
Prior to December 2018, management of BPDCN revolved around intensive chemotherapy utilizing AML (7+3 [7 days of cytarabine + 3 days of either daunorubicin or idarubicin]) or ALL/B-cell lymphoma (HCVAD [hyperfractionated cyclophosphamide/vincristine/doxorubicin/dexamethasone] or CHOP [cyclophosphamide/doxorubicin/vincristine/prednisone]) regimens.
In this trial, Pemmaraju et al first described in detail the clinical response criteria for BPDCN: normalization of peripheral blood counts; bone marrow blasts (<5%); regression of nodal, spleen, and liver masses; and 100% clearance of all skin lesions with no new lesions.